BioLineRx is trading 5.07% higher at $2.28 before the October 13, 2026 open, versus its October 12 close of $2.17; no confirmed overnight catalyst was identified.
- The move follows several recent declining closes.
- The latest company release, dated October 8, announced two GLIX1 presentations at the November Society for Neuro-Oncology meeting; no source linked that news to the pre-market rise.
- An apparent FDA-approval headline refers to APHEXDA’s 2023 approval, not a new event.